- Case report
- Open Access
- Open Peer Review
Classic Kaposi’s sarcoma - complete response to radiation therapy: a case report
Journal of Medical Case Reportsvolume 10, Article number: 322 (2016)
Classic Kaposi’s sarcoma is a lymphatic endothelial cell neoplasm usually present on the skin of the upper and lower extremities. Although it commonly affects human immunodeficiency virus positive patients, there have been some human immunodeficiency virus negative cases reported. We report an uncommon presentation of stage IV classic Kaposi’s sarcoma in an human immunodeficiency virus negative patient in Latin America with complete clinical response using only radiation therapy treatment.
A 78-year-old Mexican man with no evidence of human immunodeficiency virus infection presented with a painful widespread dermatosis with maculopapular, nodular, violaceous lesions on his legs and ulcerated lesions on his feet. A biopsy confirmed the lesions as classic Kaposi’s sarcoma. Radiotherapy treatment was delivered, prescribing a total dose of 30 Gy in 15 fractions with a complete clinical response within 15 months of follow-up.
This is an unusual case since it is uncommon to use radiation therapy as the single treatment in stage IV classic Kaposi’s sarcoma; the efficacy of the treatment is shown in the impact in our patient’s recurrence-free survival, local control, and palliation of our patient’s symptoms.
Kaposi’s sarcoma (KS) is a malignant neoplasm of lymphatic endothelial cells defined for the first time in 1872 . A Hungarian dermatologist, Moritz Kaposi, named it as “idiopathic multiple pigmented sarcoma”, also known as “Kaposi’s angiosarcoma” or “idiopathic multiple hemorrhagic sarcoma”. KS is a systemic angiomatosis with malignant evolution, which is initially manifested as multiple vascular nodules in the skin and other organs [2, 3]. Classic Kaposi’s sarcoma (CKS) mostly affects people of Mediterranean background and Jewish origin, Italy and Turkey being the countries with the highest frequency of the disease. CKS appears between the fifth and seventh decade of life and is more common in males than females with a ratio of 15 to 1.
The most frequent location is the lower extremities with cutaneous affectation and centripetal extension. Tumors and nodules can either be covered by normal skin, atrophic skin or ulcerated; some others may have a wart-like or fungal surface. The lesions can be painful, edematous and hemorrhagic, limiting patient ambulation. The damage may appear on internal organs or be only visceral without any cutaneous lesions. Despite the fact that any internal organ can be affected, it can also appear without cutaneous lesions and exclusive visceral affection. The affection of the lungs or lymph nodes it is not frequent. Death can be a consequence of generalized disease with cachexia, hemorrhage, or impairment of vital organs function by tumor growth [4, 5].
A 78-year-old Mexican man with no evidence of human immunodeficiency virus (HIV) infection presented with a history of two cardiac catheterizations, longstanding hypertension, high-risk prostate cancer treated with total androgenic blockage and radiation therapy (RT). Our patient also presented a painful widespread dermatosis with maculopapular, nodular, violaceous lesions on his legs and ulcerated lesions on his feet, limiting our patient’s ambulation for a year (Fig. 1). In order to confirm the diagnosis of CKS, an incisional biopsy was performed on our patient; the result was non-HIV-associated CKS without immunosuppression (Fig. 2). The final diagnosis was: dispersed and aggressive stage IV CKS. Our patient was not a candidate for systemic therapy due to the comorbidities and the high toxicity risk. Radiotherapy was decided as the single treatment with the Clinac iX energy 6MV equipment (Varian Medical Systems, Inc., Palo Alto, CA, USA), using two fields of treatment and 100 % of the prescription dose, giving a total dose of 3000 cGy in 15 fractions, 200 cGy per fraction, and a bolus of 0.5 cm doses to the surface. An increase in electrons for his heels with a 0.5 cm depth from the skin was considered (Fig. 3).
Treatment for classic Kaposi’s sarcoma is mainly palliative. Multidisciplinary treatment methods with different responses are applied to CKS therapy such as intralesional interferon alpha, cryotherapy, hormone therapy, laser removal, systemic chemotherapy, infrared coagulation and radiotherapy depending on the clinical form . Radiotherapy is a useful method to improve the quality of life in patients with CKS and the response to treatment usually carries minimal toxicity . CKS is generally considered sensitive to radiation therapy with good palliative and esthetic results, demonstrated with doses greater than 20 Gy . In this sense in the literature, a standard dose of treatment is not mentioned; however, radiotherapy hypofractionation has demonstrated to have an impact in terms of recurrence-free survival, toxicity, and local control . For those patients with a limited life expectancy one fraction with 800 cGy has shown to provide successful outcomes . In this case, the dose of 30 Gy in sessions of 2 Gy per fraction in combination with electron therapy in the same dosage in the lesions had a complete response on his feet, along with the relief of symptoms and improvement in life quality of our patient.
It is uncommon to use radiation therapy as the single treatment in stage IV classic Kaposi’s sarcoma, the efficacy of the treatment is shown in the impact in our patient’s recurrence-free survival, local control, and palliation of patient symptoms.
classic Kaposi’s sarcoma
Human Immunodeficiency Virus
radiotherapy or radiation therapy
Szajerka T, Jablecki J. Kaposi’s sarcoma revisited. AIDS Rev. 2007;9:230–6.
Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis. 2008;47(9):1209–15.
Antman K, Chang Y. Medical progress: Kaposi’s sarcoma. N Engl J Med. 2000;342:1027–38.
Rojo DE. Armando: Acta Medica Grupo Angeles, Sarcoma de Kaposi; resumen 11, No 1 enero-marzo. 2013
Iscovich J, Boffetta P, Winkelmann R, Brennan P. Classic Kaposi’s sarcoma as a second primary neoplasm. Int J Cancer. 1999;80:178–82.
Brambilla L, Boneschi V, Taglioni M, Ferrucci S. Staging of classic Kaposi’s sarcoma: a useful tool for therapeutic choices. Eur J Dermatol. 2003;13(1):83–6.
Cooper JS, Steinfeld AD, Lerch I. Intentions and outcomes in the radiotherapeutic management of epidemic Kaposi’s sarcoma. Int J Radiat Oncol Biol Phys. 1991;20(3):419–22.
Akmansu M, Goksel F, Erpolat OP, Unsal D, Karahacioglu E, Bora H. The palliative radiotherapy of classic Kaposi’s sarcoma of foot region: retrospective evaluation. Int J Hematol Oncol. 2014;24:147–52.
Nicolini G, Abraham S, Fogliata A, Jordaan A, Clivio A, Vanetti E, Cozzi L. Critical appraisal of volumetric-modulated arc therapy compared with electrons for the radiotherapy of cutaneous Kaposi’s sarcoma of lower extremities with bone sparing. Br J Radiol. 2013;86:20120543.
Singh NB, Lakier RH, Donde B. Hypofractionated radiation therapy in the treatment of epidemic Kaposi sarcoma--a prospective randomized trial. Radiother Oncol. 2008;88(2):211–6.
Harrison M, Harrington KJ, Tomlinson DR, Stewart JS. Response and cosmetic outcome of two fractionation regimens for AIDS-related Kaposi’s sarcoma. Radiother Oncol. 1998;46(1):23–8.
We thank Carolina Gongora, Maryssa De la Torre, and Paulina Reyes for the revision of the English version of the case report and Roman Moo, BSc for editing the images.
We declare that this case report received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Availability of data and materials
The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.
KR provided all of the patient information, coordinated the collection of information and wrote the manuscript. JZ gathered articles, collected data, and reviewed the manuscript. DH developed and participated in the treatment plan. AJ developed and participated in the treatment plan. DM provided the histological images, redacted the description of the aforementioned images, and reviewed the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.